Abstract 136P
Background
Recent studies indicated that Helicobacter pylori (H. pylori) exerts an oncogenic effect on the development of gastric diffuse large B-cell lymphoma (DLBCL). However, the effect of H. pylori status on prognosis of gastric DLBCL remains unconfirmed.
Methods
In the present study, H. pylori status was assessed by histologic examinations, supplemented by results from urease breath test and/or serological analyses where available. Staging tumours included a detailed medical history, physical examination which included peripheral lymph nodes and Waldeyer’s ring, complete hematological biochemical examinations containing serum lactate dehydrogenase (LDH), computed tomography (CT), gastric endoscopy, endoscopic ultrasonography, positron emission tomography (PET)/CT, and bone marrow aspiration and biopsy. Survival curves were estimated by Kaplan-Meier univariate analyses. The prognostic value of H. pylori was verified by both univariate and multivariate analyses.
Results
One hundred and twenty-nine patients diagnosed with primary de novo gastric DLBCL in West China Hospital of Sichuan University were included from 1st January 2009 to 31st May 2016. Over a median follow-up of 45.0 months (range 2-107), mean event-free survival (EFS) was 83.1 months (95% CI 72.7-93.5) and mean overall survival (OS) was 89.9 months (95% CI 80.9-98.9) in patients infected with H. pylori, compared with 62.0 months (95% CI 50.7–73.3) and 72.2 months (95% CI 61.6–82.9), respectively, in H. pylori-negative subgroup (P = 0.010 and P = 0.020 for differences in EFS and OS between groups, respectively). Patients with H. pylori infection had significantly better 5-year EFS and OS than H. pylori-negative subgroup (5-year EFS, 71% vs 47%, P = 0.010; 5-year OS, 79% vs 58%, P = 0.020). Older age, advanced Lugano stage, higher IPI score, and negative H. pylori status were independent negative prognostic indicators of survival outcomes.
Conclusions
H. pylori status in de novo gastric DLBCL can be a promising predictor of disease outcomes, and patients with negative H. pylori status should be followed up carefully since they tend to have a poor outlook.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract